AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12893374 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg neostigmine in the axillary plexus (NAGr)
Number of subjects: 90
Study 12893374 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (1 ml) in the axillary plexus (TGr)
Number of subjects: 90
Study 12893374 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg neostigmine subcutaneously (NSGr)
Number of subjects: 90
Study 10428228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent clamping of suction drains (clamped 55 minutes each hour, released for 5 minutes each hour for 6 hours postoperatively)
Number of subjects: 54
Study 10428228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent clamping of suction drains
Number of subjects: 54
Study 10428228 — intervention group
Group type: COMPARATOR
Intervention: Free drainage
Number of subjects: 54
Study 7744234 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin doses
Number of subjects: 77
Study 7744234 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h mean serum insulin
Number of subjects: 77
Study 7744234 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h mean serum insulin and HbA1c concentration
Number of subjects: 77
Study 7744234 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin values at 03.00 hours
Number of subjects: 77
Study 7744234 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin values at 07.00 hours
Number of subjects: 77
Study 7744234 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time hypoglycaemia
Number of subjects: 77
Study 7744234 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of insulin profiles
Number of subjects: 77
Study 1963071 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-2a interferon
Number of subjects: 56
Study 1963071 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 7028181 — intervention group
Group type: EXPERIMENTAL
Intervention: COPP (cyclophosphamide, vincristine, procarbazine, prednisone)
Number of subjects: 52
Study 7028181 — intervention group
Group type: EXPERIMENTAL
Intervention: BCVP (BCNU, cyclophosphamide, vincristine, prednisone)
Number of subjects: 52
Study 7028181 — intervention group
Group type: COMPARATOR
Intervention: CP (cyclophosphamide-prednisone)
Number of subjects: 52
Study 7028181 — intervention group
Group type: EXPERIMENTAL
Intervention: COPP
Number of subjects: 52
Study 31155169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine (1 mg/kg)
Number of subjects: 130
Study 31155169 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (1 μg/kg)
Number of subjects: 130
Study 29724749 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient bath additives
Number of subjects: 482
Study 29724749 — intervention group
Group type: COMPARATOR
Intervention: No bath additives
Number of subjects: 482
Study 27977797 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant HBV vaccine (3 or 4 doses)
Number of subjects: 364
Study 27977797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination strategies
Number of subjects: 364
Study 24754047 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF treatment (Group A)
Number of subjects: 47
Study 24754047 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (Group B)
Number of subjects: 47
Study 22729705 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture mesh fixation
Number of subjects: 110
Study 22729705 — intervention group
Group type: COMPARATOR
Intervention: Tacker mesh fixation
Number of subjects: 110
Study 20854735 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing injection (100 ml once daily for 7 days)
Number of subjects: 30
Study 20854735 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing injection
Number of subjects: 30
Study 20854735 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 30
Study 18715204 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoPen 4
Number of subjects: 35
Study 15985478 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (750 mg every 4 h for 24 h)
Number of subjects: 8
Study 15985478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12024097 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone Position (PP)
Number of subjects: 51
Study 12024097 — intervention group
Group type: COMPARATOR
Intervention: Supine Position (SP)
Number of subjects: 51
Study 10751856 — intervention group
Group type: EXPERIMENTAL
Intervention: Saw palmetto herbal blend
Number of subjects: 44
Study 10751856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9015907 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms daily)
Number of subjects: 24
Study 9015907 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (400 micrograms daily)
Number of subjects: 24
Study 1642836 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin hydrochloride (250 mg/mL in saline solution, four drops administered locally twice a day for 5 to 10 days)
Number of subjects: 60
Study 1642836 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular gentamicin sulfate (80 mg administered intramuscularly twice a day for 5 to 10 days)
Number of subjects: 60
Study 6526772 — intervention group
Group type: EXPERIMENTAL
Intervention: Padded helmet
Number of subjects: 1
Study 6526772 — intervention group
Group type: EXPERIMENTAL
Intervention: Padded helmet and padded slippers
Number of subjects: 1
Study 6526772 — intervention group
Group type: COMPARATOR
Intervention: No protective clothing
Number of subjects: 1
Study 31594878 — intervention group
Group type: EXPERIMENTAL
Intervention: De-implementation strategies to reduce test ordering
Number of subjects: 39
Study 29660207 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole/sertraline combination (ASC)
Number of subjects: 412
Study 29660207 — intervention group
Group type: COMPARATOR
Intervention: Placebo/sertraline combination (PSC)
Number of subjects: 412
Study 27388435 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy (smelled for 20 minutes twice a day over a 12-week period)
Number of subjects: 100
Study 27388435 — intervention group
Group type: COMPARATOR
Intervention: Diluted milk (control group)
Number of subjects: 100
Study 23921488 — intervention group
Group type: EXPERIMENTAL
Intervention: Focalin XR
Number of subjects: 0
Study 23921488 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerta
Number of subjects: 0
Study 23921488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin LA
Number of subjects: 0
Study 22194373 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) with distal filter protection
Number of subjects: 50
Study 22194373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrolipid plaques
Number of subjects: 50
Study 22194373 — intervention group
Group type: COMPARATOR
Intervention: Fibrocalcified plaques
Number of subjects: 50
Study 20416130 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice (DG; n=29)
Number of subjects: 78
Study 20416130 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplement with meals (SG; n=23; 50 mg Fe as amino acid chelate)
Number of subjects: 78
Study 20416130 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PG; n=26)
Number of subjects: 78
Study 18582928 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for 31-39 days (with placebo injection for 10-14 days)
Number of subjects: 2509
Study 18582928 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily subcutaneously for 10-14 days (with placebo tablet for 31-39 days)
Number of subjects: 2509
Study 18582928 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2509
Study 18582928 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 2509
Study 15981045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasoenteric feeding (test group)
Number of subjects: 100
Study 15981045 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 12054909 — intervention group
Group type: EXPERIMENTAL
Intervention: ozagrel hydrochloride (400 mg for 4 days)
Number of subjects: 4
Study 12054909 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 4
Study 10740407 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrotic syndrome patients
Number of subjects: 21
Study 7626851 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotherapy with 5-FU, folinic acid, and oxaliplatin
Number of subjects: 50
Study 7626851 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotherapy with 5-FU
Number of subjects: 50
Study 7626851 — intervention group
Group type: COMPARATOR
Intervention: Cytokine delivery (interferon alpha)
Number of subjects: 50
Study 8382753 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor, lisinopril (ACEI)
Number of subjects: 25
Study 8382753 — intervention group
Group type: COMPARATOR
Intervention: Calcium antagonist, nifedipine (CA)
Number of subjects: 25
Study 3533082 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional group psychotherapy
Number of subjects: 57
Study 3533082 — intervention group
Group type: EXPERIMENTAL
Intervention: Group assertion/relaxation training
Number of subjects: 57
Study 3533082 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 57
Study 31416333 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 26
Study 31416333 — intervention group
Group type: COMPARATOR
Intervention: Nadolol
Number of subjects: 26
Study 31416333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 28750917 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon (PEG-IFN) therapy
Number of subjects: 121
Study 27616607 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality dodgeball intervention (15 minutes for 3 consecutive days)
Number of subjects: 52
Study 27616607 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 52
Study 25318408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet system (SSTS) dispensing a 15-μg sufentanil tablet sublingually with a 20-minute lockout
Number of subjects: 0
Study 25318408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet system (SSTS)
Number of subjects: 0
Study 25318408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23871270 — intervention group
Group type: EXPERIMENTAL
Intervention: LeFort I surgery
Number of subjects: 32
Study 23871270 — intervention group
Group type: EXPERIMENTAL
Intervention: Late maxillary protraction
Number of subjects: 32
Study 23871270 — intervention group
Group type: COMPARATOR
Intervention: Combined treatments (surgery and protraction)
Number of subjects: 32
Study 21410370 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1800
Study 21410370 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 1800
Study 19505827 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal oscillation of an immersive virtual scene at 188 cm/s
Number of subjects: 10
Study 19505827 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal oscillation of an immersive virtual scene at 125 cm/s
Number of subjects: 10
Study 19505827 — intervention group
Group type: COMPARATOR
Intervention: Sinusoidal oscillation of an immersive virtual scene at lower velocities (1.2 to 125 cm/s)
Number of subjects: 10
Study 17011559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm protamine‐1 (P1) and protamine‐2 (P2) concentrations
Number of subjects: 0
Study 15496650 — intervention group
Group type: EXPERIMENTAL
Intervention: Corydalis yanhusuo and Angelicae dahuricae extracts, single oral administration
Number of subjects: 0
Study 15496650 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11132399 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O + hyperventilation (HV)
Number of subjects: 40
Study 11132399 — intervention group
Group type: EXPERIMENTAL
Intervention: O2/air + hyperventilation (HV)
Number of subjects: 40
Study 11132399 — intervention group
Group type: COMPARATOR
Intervention: N2O + normoventilation (NV)
Number of subjects: 40
Study 11132399 — intervention group
Group type: COMPARATOR
Intervention: O2/air + normoventilation (NV)
Number of subjects: 40
Study 11132399 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 40
Study 9681529 — intervention group
Group type: EXPERIMENTAL
Intervention: BrdUrd assay
Number of subjects: 390
Study 9681529 — intervention group
Group type: EXPERIMENTAL
Intervention: PCNA assay
Number of subjects: 390
Study 9681529 — intervention group
Group type: EXPERIMENTAL
Intervention: PCNA PH
Number of subjects: 390
Study 7801065 — intervention group
Group type: EXPERIMENTAL
Intervention: Low power Ga-Al-As laser treatment (22.5 joule per treatment, 15 min each, total of nine treatments over 9 weeks)
Number of subjects: 29
Study 7801065 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser treatment
Number of subjects: 29
Study 3288682 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (200-800 micrograms daily)
Number of subjects: 30
Study 3288682 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200-800 micrograms daily)
Number of subjects: 30
Study 29608590 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftriaxone/doxycycline (n = 82)
Number of subjects: 271
Study 29608590 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftriaxone/clarithromycin-hydroxychloroquine (n = 93)
Number of subjects: 271
Study 29608590 — intervention group
Group type: COMPARATOR
Intervention: ceftriaxone/placebo (n = 96)
Number of subjects: 271
Study 29608590 — intervention group
Group type: COMPARATOR
Intervention: ceftriaxone/doxycycline compared to ceftriaxone/placebo
Number of subjects: 271
Study 29608590 — intervention group
Group type: COMPARATOR
Intervention: ceftriaxone/clarithromycin-hydroxychloroquine compared to ceftriaxone/placebo
Number of subjects: 271
Study 27269205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential bilateral rTMS (600 pulses at 1 Hz followed by 1500 pulses at 10 Hz)
Number of subjects: 121
Study 27269205 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral high-frequency left (HFL)-rTMS (2100 pulses at 10 Hz)
Number of subjects: 121
Study 27269205 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 121
Study 27269205 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (bilateral, HFL-rTMS, sham)
Number of subjects: 121
Study 23638947 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmandibular implant
Number of subjects: 60
Study 23638947 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation of the mandible with an autologous bone graft followed by placement of four endosseous implants
Number of subjects: 60
Study 23638947 — intervention group
Group type: EXPERIMENTAL
Intervention: Short endosseous implants
Number of subjects: 60
Study 22448738 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil 100 mg
Number of subjects: 200
Study 22448738 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil 200 mg
Number of subjects: 200
Study 22448738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 20429382 — intervention group
Group type: EXPERIMENTAL
Intervention: Uvulopalatopharyngoplasty (UPPP)
Number of subjects: 81
Study 20429382 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio frequency plasma Uvulopalatopharyngoplasty
Number of subjects: 81
Study 18522670 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based quality improvement (EBQI) approach to smoking cessation guidelines implementation
Number of subjects: 1941
Study 18522670 — intervention group
Group type: COMPARATOR
Intervention: Usual care (mailed guidelines and VA audit-feedback reports)
Number of subjects: 1941
Study 16422307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian designs for monitoring time to severe adverse event, disease progression, and death.
Number of subjects: 0
Study 12201973 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (Carmeda or Duraflo)
Number of subjects: 0
Study 12201973 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-heparin-coated circuits)
Number of subjects: 0
Study 9681885 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy single dose
Number of subjects: 241
Study 9681885 — intervention group
Group type: COMPARATOR
Intervention: 5 Gy x4 fractionated dose
Number of subjects: 241
Study 2655366 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml 0.5% bupivacaine in 8% glucose (hyperbaric) with 60 min sitting (Group-60)
Number of subjects: 12
Study 2655366 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml 0.5% bupivacaine in 8% glucose (hyperbaric) with 2 min sitting (Group-2)
Number of subjects: 12
Study 792688 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 9
Study 792688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30830929 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-impregnated collars for dogs
Number of subjects: 6440
Study 30830929 — intervention group
Group type: COMPARATOR
Intervention: Control (uncollared villages)
Number of subjects: 6440
Study 27739217 — intervention group
Group type: EXPERIMENTAL
Intervention: CNRB
Number of subjects: 62
Study 27739217 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF
Number of subjects: 62
Study 27739217 — intervention group
Group type: EXPERIMENTAL
Intervention: CNRB + PRF
Number of subjects: 62
Study 25580933 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise as a treatment strategy
Number of subjects: 290
Study 25580933 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 290
Study 24624380 — intervention group
Group type: EXPERIMENTAL
Intervention: HP 7.5% (home application)
Number of subjects: 60
Study 24624380 — intervention group
Group type: EXPERIMENTAL
Intervention: HP 35% (in-office application)
Number of subjects: 60
Study 24624380 — intervention group
Group type: COMPARATOR
Intervention: Control (immersion in deionised water)
Number of subjects: 60
Study 21390543 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength training
Number of subjects: 8
Study 19131891 — intervention group
Group type: EXPERIMENTAL
Intervention: DAART (n = 88)
Number of subjects: 141
Study 19131891 — intervention group
Group type: COMPARATOR
Intervention: SAT (n = 53)
Number of subjects: 141
Study 17971595 — intervention group
Group type: EXPERIMENTAL
Intervention: Arzoxifene 20 mg daily
Number of subjects: 352
Study 17971595 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg daily
Number of subjects: 352
Study 15049934 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide plus rosiglitazone
Number of subjects: 252
Study 15049934 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide
Number of subjects: 252
Study 15049934 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 252
Study 11430936 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 g daily)
Number of subjects: 30
Study 11430936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9601653 — intervention group
Group type: EXPERIMENTAL
Intervention: CNTF null mutation
Number of subjects: 0
Study 9601653 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8306551 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pretreatment
Number of subjects: 0
Study 8306551 — intervention group
Group type: COMPARATOR
Intervention: No glucocorticoids (Control)
Number of subjects: 0
Study 3407868 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 30 micrograms/kg
Number of subjects: 27
Study 3407868 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 60 micrograms/kg
Number of subjects: 27
Study 3407868 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 80 micrograms/kg
Number of subjects: 27
Study 3407868 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (any dose)
Number of subjects: 27
Study 3407868 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 60 micrograms/kg and 80 micrograms/kg
Number of subjects: 27
Study 3407868 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine and glycopyrronium (fixed 5:1 ratio)
Number of subjects: 27
Study 686346 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane concentrations ranging from 0.5 to 2.0 vol.%
Number of subjects: 10
Study 686346 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptanaesthesia (control)
Number of subjects: 10
Study 30892997 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning (ACP) and usual care
Number of subjects: 141
Study 30892997 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 141
Study 28951711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (advised about urinary cotinine levels by telephone)
Number of subjects: 134
Study 28951711 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (not advised about urinary cotinine levels)
Number of subjects: 134
Study 25858202 — intervention group
Group type: EXPERIMENTAL
Intervention: High tryptophan diet
Number of subjects: 25
Study 25858202 — intervention group
Group type: COMPARATOR
Intervention: Low tryptophan diet
Number of subjects: 25
Study 22771287 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervising for Home Safety program
Number of subjects: 0
Study 22771287 — intervention group
Group type: COMPARATOR
Intervention: Control program focusing on child nutrition and active lifestyles
Number of subjects: 0
Study 22764361 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 208
Study 22764361 — intervention group
Group type: COMPARATOR
Intervention: Usual care (institutional care)
Number of subjects: 208
Study 22764361 — intervention group
Group type: COMPARATOR
Intervention: Never-institutionalized
Number of subjects: 208
Study 22764361 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care (early placement before age 24 months)
Number of subjects: 208
Study 22764361 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline cognitive ability
Number of subjects: 208
Study 20494902 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 311